Pharma
The hub expands the company's research and development footprint in the region and hastens the development of AI-powered digital health technologies.
They will collaborate on identifying novel therapeutic drug candidates for lung cancer.
The company will use the funds to expand in Asian and U.S. markets, advance its AI algorithms and grow its workforce.
The CRISPR therapy, HG202, was conceived using AI and machine learning and aims to treat individuals with neovascular age-related macular degeneration.
Cuban told MobiHealthNews that he advocates for Harris because she announced she would take on non-pass-through PBMs and introduce drug transparency.
Also, Mediwhale raised $12 million for its United States expansion.
The pharma giant will integrate more than 20 AI algorithms from eight collaborators into its navify Digital Pathology enterprise software to help improve pathology workflows.
AlphaProteo was created to advance drug design and disease understanding by helping researchers configure high-strength proteins that bind to molecules.
The collaboration will leverage Genetic Leap's RNA-targeted AI platform to create genetic medicines against selected targets.
It enables the rapid monitoring of L-dopa levels, informing its optimal dosage adjustment.